Immunomic Therapeutics Expands Board of Directors with Appointments of Two New Members
Immunomic Therapeutics, Inc., (ITI), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it has appointed Steve Sang Young Park and Robert V. Ahlgren as new members to its Board of Directors, expanding the board to twelve members.
- Immunomic Therapeutics, Inc., (ITI), a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it has appointed Steve Sang Young Park and Robert V. Ahlgren as new members to its Board of Directors, expanding the board to twelve members.
- We are pleased to welcome Steve and Robert to Immunomics Board.
- In such role, he was responsible for equity capital markets activities for Macquarie Group in Korea.
- He currently serves on the Board of Directors of GS Global and on the Board of Trustees of East Asia Institute.